Search - tctmd.com

Displaying 961 - 980 of 1374

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Daily News

Societies Issue Recommendations for Operators, Institutions Offering LAA Closure Procedures

L.A. McKeown

December 10, 2015

News Industry News

Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis

December 07, 2015

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Daily News

关于人工生物瓣膜血栓形成的新发现可影响监测和研究

Caitlin E. Cox

November 23, 2015

News Daily News

Nuevos Hallazgos sobre la Trombosis de la Válvula Bioprotésica Tienen Implicaciones en Materia de Vigilancia e Investigación

Caitlin E. Cox

November 23, 2015

News Daily News

New Findings on Bioprosthetic Valve Thrombosis Have Implications for Surveillance, Research

Caitlin E. Cox

November 23, 2015

News Industry News

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

November 19, 2015

News Daily News

Good News, Bad News Week for Watchman LAA Occluder

Shelley Wood

November 12, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Features

From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing

Todd Neale

November 08, 2015

News Conference News AHA 2015

Is Watchman Cost-effective? That Depends Where You Look

Todd Neale

November 07, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Todd Neale

October 26, 2015

$Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?$

Presentation TCT 2015

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

Presenter: Carlo Briguori, Roxana Mehran, Carey D. Kimmelstiel

October 15, 2015

Presentation TCT 2015

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

Presentation TCT 2015

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Advertisement

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Societies Issue Recommendations for Operators, Institutions Offering LAA Closure Procedures

Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

关于人工生物瓣膜血栓形成的新发现可影响监测和研究

Nuevos Hallazgos sobre la Trombosis de la Válvula Bioprotésica Tienen Implicaciones en Materia de Vigilancia e Investigación

New Findings on Bioprosthetic Valve Thrombosis Have Implications for Surveillance, Research

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

Good News, Bad News Week for Watchman LAA Occluder

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing

Is Watchman Cost-effective? That Depends Where You Look

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content